Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705263 | 0.84 | FOLH1 (0.59) | ENPP2MMP3FFAR1MRGPRX4 | |
| SCHEMBL29471974 | 0.84 | FOLH1 (0.59) | ENPP2MMP3FFAR1MRGPRX4 | |
| SCHEMBL19014330 | 0.83 | ENPP2 (0.47) | ENPP2MMP3FFAR1NPC1LMNA | |
| SCHEMBL6459667 | 0.83 | MEN1 (0.61) | MAOBMAOAIL4I1MRGPRX4 | |
| SCHEMBL2857119 | 0.82 | ENPP2 (0.50) | MAOBENPP2MMP3MAOAFFAR1 | |
| SCHEMBL11459736 | 0.82 | ENPP2 (0.50) | ENPP2MMP3FFAR1MRGPRX4NPC1 | |
| SCHEMBL5437219 | 0.81 | SLC7A5 (0.55) | ENPP2MMP3FFAR1MRGPRX4HTT | |
| SCHEMBL3407379 | 0.81 | ENPP2 (0.46) | MAOBENPP2MMP3FFAR1MRGPRX4 | |
| SCHEMBL29539688 | 0.81 | LOXL2 (0.64) | ENPP2MRGPRX4NPC1MAPTHTT | |
| SCHEMBL40562 | 0.81 | LOXL2 (0.64) | ENPP2MRGPRX4NPC1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| EP-0733037-A1 | ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS | UNIVERSITY OF BRISTOL (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015941-A1 | ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS | UNIVERSITY OF BRISTOL (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189836-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | MAOB 2444/4885ENPP2 393/4885MMP3 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.